NCT01561014View on ClinicalTrials.gov

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the StomachSquamous Cell Carcinoma of the EsophagusStage II Esophageal CancerStage II Gastric CancerStage III Esophageal CancerStage III Gastric Cancer
Interventions
DRUG

erlotinib hydrochloride

Given PO

DRUG

oxaliplatin

Given IV

DRUG

fluorouracil

Given IV

RADIATION

radiation therapy

Undergo radiotherapy

PROCEDURE

conventional surgery

Undergo surgical resection

OTHER

immunohistochemistry staining method

Correlative study

PROCEDURE

positron emission tomography

Correlative study

PROCEDURE

computed tomography

Correlative study

PROCEDURE

laboratory biomarker analysis

Correlative study

GENETIC

gene expression analysis

Correlative study

RADIATION

fludeoxyglucose F 18

Undergo F18 PET and CT scan

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT01561014 - Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | Biotech Hunter | Biotech Hunter